Flags

Financial distress

Reyon Pharmaceutical

KSC:102460 · KR7102460003

PharmaceuticalsSmall

360

Medium confidence — indicative

Value44

Profit price87

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price34

Price/Sales28

EV / Gross Profit23

Price/Book51

Quality43

Returns on capital49

Return on Capital46

Cash Return on Capital52

Return on Equity49

Profit margins19

EBIT Margin7

Gross Profitability30

Cash backing50

Accruals67

Owner Earnings Margin32

Growth42

Sales growth27

Profit growth37

Profit Growth73

Owner Earnings Growth1

Reinvestment18

Price momentum48

Safety33

Debt load13

Debt serviceability28

Refinancing54

Debt Payback1

Liquidity19

Sentiment48

Analyst ratings—

Expectations trend—

Market mood79

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Reyon Pharmaceutical doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Founded1964

Employees7

Websitereyonpharm.co.kr

ISINKR7102460003

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

OphthalmologyCardiovascularNeurologyOncologyGenetics

Description

Analysis

Middle-of-the-road

REYON Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Reyon Pharmaceutical with its peers

Kyongbo Pharmaceutical

KSC:214390

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Hana Pharm

KSC:293480

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kukje Pharma

KSC:002720

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samsung Pharm

KSC:001360

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samil Pharmaceutical

KSC:000520

CountrySouth Korea

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

PharmGen Science

KSC:004720

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →